Clinical research is crucial to the development of new treatments and new uses for current medications. Clinical research studies, or trials, test investigational drugs or devices to determine efficacy.
Treating participants with respect and dignity, while placing their safety as top priority during a clinical trial are of the utmost importance to IU Health Arnett Clinical Research.
IU Health Arnett Clinical Research has conducted clinical trials in Lafayette, Indiana since 1990. Bamidele Adesunloye, MD, MS, FACP is the medical director of clinical research at IU Health Arnett. Dr. Adesunloye is Board Certified in Medical Oncology. At IU Health Arnett Clinical Research, we are indeed Testing Today for the Treatments of Tomorrow.
"By participating in clinical research trials, we provide an opportunity for our physicians to be on the leading edge of medical science and provide patients with earlier access to promising new medicines and technology." - Dr. Bamidele Adesunloye
Clinical research is crucial to the development of new treatments and new uses for current medications. Clinical research studies, or trials, test investigational drugs or devices to determine efficacy.
Treating participants with respect and dignity, while placing their safety as top priority during a clinical trial are of the utmost importance to IU Health Arnett Clinical Research.
IU Health Arnett Clinical Research has conducted clinical trials in Lafayette, Indiana since 1990. Bamidele Adesunloye, MD, MS, FACP is the medical director of clinical research at IU Health Arnett. Dr. Adesunloye is Board Certified in Medical Oncology. At IU Health Arnett Clinical Research, we are indeed Testing Today for the Treatments of Tomorrow.
"By participating in clinical research trials, we provide an opportunity for our physicians to be on the leading edge of medical science and provide patients with earlier access to promising new medicines and technology." - Dr. Bamidele Adesunloye
C-Diff – (Dr. Meyer’s study) – Rebiotix 2017-01: A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection
We are currently participating in cancer trials for the treatment of:
Helsinn NEPA-17-05: A Ph 3b, multicenter, randomized, double-blind, double-dummy, active controlled, parallel group study to assess the efficacy and safety of IV fosnetupitant/palonosetron (260 mg/0.25mg) combo (IV NEPA FDC) compared to oral netupitant/palonosetron (300mg/0.5mg) combo (Akynzeo) for the prevention of chemo-induced nausea and vomiting in AC naive female breast cancer patients receiving AC chemo
Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Pfizer B9991016: A randomized double-blind PH 3 study of Avelumab in combo with standard of care chemoradiotherapy (cisplatin plus definitive radiation therapy) vs. standard of care chemoradiotherapy in the front-line treatment of patients with locally advanced squamous cell carcinoma of the head and neck
Dx Biosamples DxB-062 NSCLC: Collection of fresh blood from treatment naïve or progressing Stage IV M1b NSCLC cancer patients
Dx Biosamples DxB-093: Collection of fresh blood from PD1/PDL1 treatment naïve NSCLC cancer patients.
Astellas ONC-MA-1004: A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States
C-Diff – (Dr. Meyer’s study) – Rebiotix 2017-01: A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection
We are currently participating in cancer trials for the treatment of:
Helsinn NEPA-17-05: A Ph 3b, multicenter, randomized, double-blind, double-dummy, active controlled, parallel group study to assess the efficacy and safety of IV fosnetupitant/palonosetron (260 mg/0.25mg) combo (IV NEPA FDC) compared to oral netupitant/palonosetron (300mg/0.5mg) combo (Akynzeo) for the prevention of chemo-induced nausea and vomiting in AC naive female breast cancer patients receiving AC chemo
Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Pfizer B9991016: A randomized double-blind PH 3 study of Avelumab in combo with standard of care chemoradiotherapy (cisplatin plus definitive radiation therapy) vs. standard of care chemoradiotherapy in the front-line treatment of patients with locally advanced squamous cell carcinoma of the head and neck
Dx Biosamples DxB-062 NSCLC: Collection of fresh blood from treatment naïve or progressing Stage IV M1b NSCLC cancer patients
Dx Biosamples DxB-093: Collection of fresh blood from PD1/PDL1 treatment naïve NSCLC cancer patients.
Astellas ONC-MA-1004: A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States
For more information about IU Health Arnett oncology/hematology clinical trials, or if you would like to participate, please contact:
Julia Keenoy, CCRP
Coordinator
Clinical Research
Phone: 765.838.6848
Fax: 765.448.7599
Email
Stephanie Middleton, LPN, CCRC
Coordinator
Clinical Research
Phone: 765.838.6871
Fax: 765.448.7599
Email
Celine Withers, RPh BCOP
Administrative Director
Indiana University Health Arnett Cancer Center
Phone: 765.838.7312
Fax: 765.448.7599
Email
For more information about IU Health Arnett oncology/hematology clinical trials, or if you would like to participate, please contact:
Julia Keenoy, CCRP
Coordinator
Clinical Research
Phone: 765.838.6848
Fax: 765.448.7599
Email
Stephanie Middleton, LPN, CCRC
Coordinator
Clinical Research
Phone: 765.838.6871
Fax: 765.448.7599
Email
Celine Withers, RPh BCOP
Administrative Director
Indiana University Health Arnett Cancer Center
Phone: 765.838.7312
Fax: 765.448.7599
Email